Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.107.20 CHF
Change Today +0.20 / 0.19%
Volume 18.6K
YPSN On Other Exchanges
YPSN is not on other exchanges.
As of 11:43 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

ypsomed holding ag-reg (YPSN) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/31/15 - SFr.107.70
52 Week Low
01/22/15 - SFr.75.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for YPSOMED HOLDING AG-REG (YPSN)

Related News

No related news articles were found.

ypsomed holding ag-reg (YPSN) Related Businessweek News

No Related Businessweek News Found

ypsomed holding ag-reg (YPSN) Details

Ypsomed Holding AG develops, manufactures, and sells injection pens for pharmaceutical and biotech companies worldwide. The company operates in two segments, Delivery Devices and Diabetes Direct Business. The Delivery Devices segment offers products, such as pen systems, pen needles, infusion sets, and other injection moldings products. The Diabetes Direct Business sells and trades devices for the self-monitoring of blood glucose levels, as well as infusion pumps, accessories, and other day-to-day items for diabetics. The company offers insulin pumps, injection systems, and pen needles for the treatment of diabetes, growth disorders, infertility, and other therapeutic areas; pen needles under the mylife Diabetescare brand for the treatment of diabetes; needles for its mylife Clickfine DiamondTip injection pens; and mylife YpsoPump insulin pumps. Ypsomed Holding AG markets its products through biotech and pharmaceutical partners, as well as through its own distribution network and independent distributors. The company was founded in 1984 and is headquartered in Burgdorf, Switzerland.

1,013 Employees
Last Reported Date: 05/20/15
Founded in 1984

ypsomed holding ag-reg (YPSN) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.516.9K
Senior Vice President of Legal & Intellectual...
Total Annual Compensation: --
Compensation as of Fiscal Year 2015.

ypsomed holding ag-reg (YPSN) Key Developments

Ypsomed Holding AG and Polfa Tarchomin S. A. Sign Supply Agreement for Reusable Insulin Pen

Ypsomed Holding AG signed a supply agreement with Polfa Tarchomin S. A. for reusable insulin pen, YpsoPen. The YpsoPen is being introduced to the Polish market and will be used to administer Polfa Tarchomin's insulin. Negotiations are in place to expand cooperation to other countries. The PolhuminPen, an injection system based on the YpsoPen platform, was introduced to Europe for the first time at the beginning of June in 2015. Polfa Tarchomin markets the reusable insulin pen together with its insulin Polhumin.

Ypsomed Holding AG Proposes Dividend for the Fiscal Year 2015

Ypsomed Holding AG will propose the dividend for the fiscal year 2015 to be doubled to CHF 0.60 per share.

Ypsomed Holding AG Reports Earnings Results for the Fiscal Year Ended March 2015; Provides Earnings Guidance for the Fiscal Year 2016

Ypsomed Holding AG reported earnings results for the fiscal year ended March 2015. For the period, the company’s net profit jumped by 43% to CHF 19.4 million, boosted by the strong sales performance of all units, as well as process and costs optimization. The company noted net profit growth was slowed down by the surge in the Swiss franc and an impairment of CHF 1.7 million related to the company's participation in Bionime. Earnings before interest and tax (EBIT) surged by more than 80% to CHF 28.5 million. Sales amounted to CHF 306.6 million, an increase of 11% on the year. The company announced that it expects sales in fiscal 2016 to grow by around 10%. EBIT is expected to amount to CHF 35 million.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
YPSN:SW SFr.107.20 CHF +0.20

YPSN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Antares Pharma Inc $2.09 USD +0.12
Bioject Medical Technologies Inc $0.05 USD 0.00
Terumo Corp ¥3,200 JPY -50.00
Unilife Corp $1.75 USD -0.02
West Pharmaceutical Services Inc $59.97 USD +0.19
View Industry Companies

Industry Analysis


Industry Average

Valuation YPSN Industry Range
Price/Earnings 69.9x
Price/Sales 4.4x
Price/Book 5.6x
Price/Cash Flow 70.1x
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YPSOMED HOLDING AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at